Drug intelligence / Profile preview

JNJ-88260237

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Oral

Overview

JNJ-88260237 is an orally administered small molecule drug developed by Janssen Research & Development. It is a new molecular entity currently in Phase 1 clinical trials. The specific mechanism of action has not been disclosed. The drug is being investigated primarily for urogenital diseases, with chronic kidney disease identified as an active indication. Clinical studies to date have focused on evaluating the safety and tolerability of single ascending doses in healthy participants.

Beyond the preview

Go deeper on JNJ-88260237.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-88260237.

Explore the full profile